Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gentamicin + metronidazole + rifaximin
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antibiotic regimen consisting of gentamicin, metronidazole, and rifaximin. This three-drug combination has been used for treating refractory Crohn's disease, pyoderma gangrenosum, small intestinal bacterial overgrowth, and resistant Clostridium difficile infections. The combination leverages the complementary antimicrobial properties of each component: gentamicin (an aminoglycoside targeting Gram-negative bacteria), metronidazole (effective against anaerobes), and rifaximin (a non-systemic antibiotic that inhibits bacterial RNA synthesis).
02
Targets
Beyond the preview
Go deeper on gentamicin + metronidazole + rifaximin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gentamicin + metronidazole + rifaximin.